The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
Abstract
BACKGROUND: Trials have shown a beneficial effect of n-3 polyunsaturated fatty acids in patients with a previous myocardial infarction or heart failure. We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. METHODS: In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were followed by a network of 860 general practitioners in Italy. Eligible patients were men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction. Patients were randomly assigned to n-3 fatty acids (1 g daily) or placebo (olive oil). The initially specified primary end point was the cumulative rate of death, nonfatal myocardial infarction, and nonfatal stroke. At 1 year, after the event rate was found to be lower than anticipated, the primary end point was revised as time to death from cardiovascular causes or admission to the hospital for cardiovascular causes. RESULTS: Of the 12,513 patients enrolled, 6244 were randomly assigned to n-3 fatty acids and 6269 to placebo. With a median of 5 years of follow-up, the primary end point occurred in 1478 of 12,505 patients included in the analysis (11.8%), of whom 733 of 6239 (11.7%) had received n-3 fatty acids and 745 of 6266 (11.9%) had received placebo (adjusted hazard ratio with n-3 fatty acids, 0.97; 95% confidence interval, 0.88 to 1.08; P=0.58). The same null results were observed for all the secondary end points. CONCLUSIONS: In a large general-practice cohort of patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity. (Funded by Società Prodotti Antibiotici and others; ClinicalTrials.gov number, NCT00317707.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [23]
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [23]
In the citing paper
“proposing that regardless of the dose of O3FA supplementation implemented in the trials and potential-related benefits on CV outcomes, O3FA supplementation may increase the risk for AF.”
From Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials (2021) · cites this paper as [5]
In the citing paper
“Even lower doses of O3FA supplementation has shown a potential signal for increased risk for AF,2,4,5”
From Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials (2021) · cites this paper as [5]
In the citing paper
“consistent with habitual excess energy intakes as small as ~50 kcal/day explaining the gradual weight gain occurring in most individuals.40”
From Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review (2016) · cites this paper as [40]
Citations
Cites
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014682.14181.f2 · Cited by 1,311
Roncaglioni, M. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03539-x · Cited by 993
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
n–3 Fatty Acids in Cardiovascular Disease
Caterina, R. D. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1008153 · Cited by 572
Rischio and Prevenzione Investigators (2010) · Trials · doi:10.1186/1745-6215-11-68 · Cited by 24
Roccatagliata, D. V., Avanzini, F., Monesi, L., Caimi, V., Lauri, D., Longoni, P., Marchioli, R., Tombesi, M., Tognoni, G., Roncaglioni, M. C., et al. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.4.507 · Cited by 20
How general practitioners perceive and grade the cardiovascular risk of their patients
Roncaglioni, M. C., Avanzini, F., Roccatagliata, D. V., Monesi, L., Tamayo-Benitez, D., Tombesi, M., Caimi, V., Longoni, P., Lauri, D., Barlera, S., et al. (2004) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000129737.84851.99 · Cited by 16
Cited by
Sorted by citations
Items 401–500 of 511
Role and Importance of Health Claims in the Nutraceutical and Functional Food Markets
Aryee, A. N. A., & Boye, J. I. (2014) · Wiley eBooks · doi:10.1002/9781118504956.ch12 · Cited by 5
Sabbour, H. M., Bhatt, D. L., Elhenawi, Y., Aljaberi, A. K., Bennani, L., Fiad, T. M., Hasan, K. Y., Hashmani, S., Hijazi, R. A., Khan, Z., et al. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07519-z · Cited by 4
Hamaya, R., Cook, N. R., Sesso, H. D., Buring, J. E., & Manson, J. E. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.02.028 · Cited by 4
Hermans, M. P., Bouénizabila, E., Amoussou-Guénou, D., Ahn, S. A., & Rousseau, M. F. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0226-z · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Messori, A., Fadda, V., Maratea, D., & Trippoli, S. (2013) · Heart & Lung · doi:10.1016/j.hrtlng.2013.06.002 · Cited by 4
Sheppard, J. P., Palatnic, L., Lakshmanan, S., Drago, T., Bhogal, J., Roy, S. K., Bhatt, D. L., Budoff, M. J., & Nelson, J. R. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2025.102149 · Cited by 3
Management of Cardiovascular Disease in Women
Mieszczanska, H. Z., & Velarde, G. P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5517-1 · Cited by 3
Úbeda, N., Achón, M., & Varela‐Moreiras, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801816-3.00044-3 · Cited by 3
Minihane, A. M. (2017) · Nutrition Bulletin · doi:10.1111/nbu.12302 · Cited by 3
Dwiputra, B., Ambari, A. M., Desandri, D. R., Purwowiyoto, B. S., Radi, B., Pandhita, B. A. W., Fatrin, S., & Santoso, A. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.2.89 · Cited by 3
Performance Analysis of Classification Methods for Cardio Vascular Disease (CVD)
Kumar, N. K., Tulasi, R. L., & Vigneswari, D. (2020) · Lecture notes in electrical engineering · doi:10.1007/978-981-15-5341-7_93 · Cited by 3
Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack
Katz, B. S., & Flemming, K. D. (2014) · Neurosurgical FOCUS · doi:10.3171/2013.10.focus13402 · Cited by 3
Dietary Fatty Acids and Cardiovascular Disease: A review
Prates, R. E., von Frankenberg, A. D., & Rodrigues, T. D. C. (2015) · Clinical & Biomedical Research · doi:10.4322/2357-9730.56681 · Cited by 3
Primary and Secondary Prevention of Ischemic Heart Disease in Women
Kohli, P. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0518-5 · Cited by 3
Genomics and Pharmacogenomics of Lipid-Lowering Therapies
Docherty, K. F., & Padmanabhan, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00031-1 · Cited by 3
Rizos, E. C., & Elisaf, M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1134462 · Cited by 3
Fish consumption, fish oils, and cardiovascular events: still waiting for definitive evidence
Ridker, P. M. (2016) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.143339 · Cited by 3
Chronic Kidney Disease in Diabetes: Is Fish Oil the Answer?
Gnudi, L. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000543588 · Cited by 2
Nguyen, N. Q., Ta, K.-N. T., & Chuang, K.-J. (2026) · Cerebrovascular Diseases · doi:10.1159/000550330 · Cited by 2
Mason, R. P., & Jacob, R. F. (2017) · Springer series in biophysics · doi:10.1007/978-3-319-66601-3_3 · Cited by 3
Singh, N., Dove, E., & Bhatt, D. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00019-4 · Cited by 3
Rifkin, E., & Lazris, A. (2014) · Springer eBooks · doi:10.1007/978-3-319-11544-3_22 · Cited by 2
Taouktsi, N., Papageorgiou, S. Τ., Tousinas, G., Papanikolopoulou, S., Grammatikopoulou, M. G., Giannakoulas, G. A., & Goulis, D. G. (2022) · HORMONES · doi:10.1007/s42000-022-00396-5 · Cited by 2
Sheppard, J. P., Lakshmanan, S., Palatnic, L., Dahal, S., Roy, S. K., Bhatt, D. L., Budoff, M. J., & Nelson, J. R. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2538404 · Cited by 2
Management of Moderate Hypertriglyceridemia in Childhood and Adolescence
Kavey, R.-E. W. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0484-7 · Cited by 2
RBC omega-3 predicts risk for death
Harris, W. S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.911 · Cited by 2
Liver and Gastrointestinal Pharmacology
Nguyen‐Lee, J., Nguyen, C., & Bagdasarjana, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-48110-6.00032-6 · Cited by 2
Omega-3 Polyunsaturated Fatty Acids in Patients with Hypertriglyceridemias and Atherosclerosis
Susekov, A. V. (2021) · Kardiologiia · doi:10.18087/cardio.2021.6.n1578 · Cited by 2
Limited impact of omega-3 fatty acids in patients with multiple cardiovascular risk factors
Calder, P. C. (2013) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2013-101440 · Cited by 2
Effects of Mediterranean Diet on Endothelial Function
Merino, J., KONES, R. J., & Ros, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812348-5.00025-8 · Cited by 2
Eicosapentaenoic Acid and Prevalence of Cardiovascular Disease in Hemodialysis Patients
Honda, T., Kishi, S., Furukawa, E., Ambe, H., Kurata, Y., Ichikawa, M., Aoe, M., Ohara, K., Furuse, S., Saito, K., et al. (2018) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12677 · Cited by 2
Effects and Issues of Diet Fat on Cardiovascular Metabolism
Nishikawa, Y. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.93261 · Cited by 2
Unsolved Antiatherogenic Mechanism of n-3 Polyunsaturated Fatty Acids
Kawashiri, M., Tada, H., & Yamagishi, M. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1252 · Cited by 2
Abuknesha, N. R., O’Keefe, J. H., Qian, F., Tintle, N. L., Lin, Y., Sun, Y., Qian, H.-Z., Aisen, P. S., Albert, C. M., Aronson, W. J., et al. (2026) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.125.014785 · Cited by 1
Mattumpuram, J., Maniya, M. T., Noman, A., Fernandes, C. A. L., Tahir, M. F., Khan, R., Hamza, M., Jaiswal, V., Ali, K., Sathian, B., et al. (2025) · Clinical and Translational Discovery · doi:10.1002/ctd2.70094 · Cited by 1
Myśliwiec, A., Leksa, D., Bartusik‐Aebisher, D., & Aebisher, D. (2026) · Journal of Applied Biomedicine · doi:10.32725/jab.2026.007 · Cited by 1
Li, D., Shum, C., Khoo, A., Shi, T., Green, M. R., Mejía, S. B., Khan, T. A., Chiavaroli, L., Sievenpiper, J. L., & Metherel, A. H. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100670 · Cited by 1
Walter, E., Torelli, F., & Barbui, T. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06229-w · Cited by 1
Jiang, L., Yuan, P., Chen, H., Fang, X., & Lan, P. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag077 · Cited by 1
Combination Therapy with Statins
Singh, A., & Davidson, M. H. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.005 · Cited by 1
Lifestyle Changes, CAM, and Kidney Stones: Heart Health = Kidney Health
Moyad, M. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8492-9_8 · Cited by 1
Bajnok, L. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29797 · Cited by 1
Peña, Á. A. G., Múñoz, Ó., Fernández, D., Higuera, A. M., Ruiz, Á. J., Montoya, P. A., Toro, J. M., Arteaga, J. M., Villamizar, A. M., Sánchez, G., et al. (2015) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2015.04.004 · Cited by 1
Flaskerud, J. H. (2015) · Issues in Mental Health Nursing · doi:10.3109/01612840.2014.994691 · Cited by 1
Omega-3-Fettsäuren in der Medizin: Mechanismen, klinische Evidenz und Kontroversen
Reiner, M. F., Stivala, S., Camici, G. G., & Beer, J. H. (2014) · Praxis · doi:10.1024/1661-8157/a001593 · Cited by 1
Complementary and Alternative Medicine and Lifestyle Changes and Prostate Cancer
Moyad, M. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8492-9_7 · Cited by 1
The Role of Omega-3 Fatty Acids in Dyslipidemias
Brandt, E. J., & Davidson, M. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_5 · Cited by 1
Vilar-González, S., Bloomfield, D. J., & Noble, M. E. M. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.09.013 · Cited by 1
How important are triglycerides as risk factors?
D’Addato, S., Palmisano, S., & Borghi, C. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000438 · Cited by 1
McQueen, C. E., & Orr, K. K. (2015) · The American Pharmacists Association eBooks · doi:10.21019/9781582122250.ch51 · Cited by 1
COPPLE, T. M., & Ciffone, N. A. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000526627.04268.80 · Cited by 1
Плавинский, С. Л., & Barinova, A. N. (2017) · Medicina · doi:10.29234/2308-9113-2017-5-4-8-20 · Cited by 1
Translating Evidence From Clinical Trials of omega-3 Fatty Acids to Clinical Practice
Nelson, A. J., & Nicholls, S. J. (2020) · Future Cardiology · doi:10.2217/fca-2019-0031 · Cited by 1
Moyad, M. A. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0425-9_12 · Cited by 1
Peskin, B. S. (2013) · Food and Nutrition Sciences · doi:10.4236/fns.2013.411147 · Cited by 1
RetractedVoeding bij diabetes mellitus type 2
van Wijland, H. (2013) · TvPO · doi:10.1007/s12503-013-0063-z · Cited by 1
Abbott, A. L., & Goldstein, L. B. (2014) · Stroke · doi:10.1161/strokeaha.113.004328 · Cited by 1
Effects of Omega-3 Fatty Acids in Myocardial Infarction
Lee, S. Y., Yi, Y. H., & Tak, Y. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-40458-5_33 · Cited by 1
Effects of Dietary Omega-3 Fatty Acid Consumption
Zanwar, A. A., Joshi, A., & Hegde, M. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811959-4.00025-0 · Cited by 2
Bentz, A. J., Netland, P. J., Newman, W. P., Froemke, L. L., Miller, R. R., & Schiele, R. L. (2018) · Europe PMC (PubMed Central) · Cited by 1
Association of polyunsaturated fatty acids treatment with coronary mortality. A meta-analysis
Плавинский, С. Л., Barinova, A. N., & Danishevski, K. D. (2019) · Kardiologiia · doi:10.18087/cardio.n680 · Cited by 1
Defining the Role of Icosapent Ethyl in Clinical Practice
Chatterjee, S., Hajra, A., Bandyopadhyay, D., Ghosh, R. K., & DEEDWANIA, P. C. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00402-4 · Cited by 1
Effects of omega-3 fatty acids, vitamins, and chelation therapy in patients with heart diseases
Joo, S.-J. (2021) · Journal of Medicine and Life Science · doi:10.22730/jmls.2021.18.1.1 · Cited by 1
General Principles of Nutrition Support in Cardiac Rehabilitation
Gohlke, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-47738-1_2 · Cited by 1
Thomas, P., Coates, P. M., & Haggans, C. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-66162-1.00035-4 · Cited by 1
Evidence-Based Family Medicine
Pohl, S., & Hastings, K. (2016) · Springer eBooks · doi:10.1007/978-3-319-04414-9_5 · Cited by 1
Tatsuno, I. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed063 · Cited by 1
Impact of Diabetes Mellitus and the Metabolic Syndrome on the Female Heart
Antonetti, I., & Velarde, G. (2013) · Springer eBooks · doi:10.1007/978-1-4471-5517-1_13
Zhang, H., Zhang, J., Wang, H., Su, X., & Teng, L. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.16.6841
n-3 fatty acids provide little benefit
Cully, M. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.82
Why Fish Oil Fails to Prevent or Improve CVD: A 21st Century Analysis
Peskin, B. S. (2013)
n-3 polyunsaturated fatty acids to heal the broken heart
Grenon, S. M., & Conte, M. S. (2013) · Clinical Lipidology · doi:10.2217/clp.13.58
Dallongeville, J. (2015) · Cahiers de Nutrition et de Diététique · doi:10.1016/s0007-9960(15)30017-1
Omega-3-Fettsäuren wirken nicht wie erhofft gegen Arteriosklerosefolgen
Schloot, N. C. (2013) · Info Diabetologie · doi:10.1007/s15034-013-0425-1
Ernährung und Nahrungsergänzungsmittel zur Prävention
Zyriax, B. ‐. (2016) · Der Gynäkologe · doi:10.1007/s00129-016-3854-9
À propos de l’effet additionnel des oméga 3 chez des patients cardiaques multimédiqués
Bourre, J. M. (2014) · Pratiques en nutrition · doi:10.1016/j.pranut.2014.03.010
Diet Modification After Acute Coronary Events
de Keizer, L., & Chow, C. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418680-4.00031-2
ω-3 Fatty Acid Supplementation in Patients with Risk Factors: A Randomized Trial
Brett, A. S. (2013) · Journal watch · doi:10.1056/jw201305080000001
Combined bioactive approach over atherosclerosis risk biomarkers
Scolaro, B. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2017.tde-07122017-163754
N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease
Barringer, T. A., Harris, W. S., Fleming, J. A., & Kris‐Etherton, P. M. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_21 · Cited by 1
Ernährung in der Prävention und Therapie der koronaren Herzkrankheit
Zyriax, B., & Windler, E. E. T. (2018) · Aktuelle Ernährungsmedizin · doi:10.1055/a-0630-2465
Acides gras oméga 3 à longue chaîne et risque cardiovasculaire, revue critique
Delarue, J. (2019) · Pratiques en nutrition · doi:10.1016/j.pranut.2019.05.004
Essential Micronutrients: Vitamins and Essential Fatty Acids
Block, J. H. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc067.pub3
Kardiovaskuläre Prophylaxe: Wenn man Surrogatmarker „therapiert“
Erdmann, E. (2015) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2015.09.18.08
(2013) · Circulation · doi:10.1161/cir.0b013e3182a3672b
Kim, J.-M., & Park, M.-S. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_10
Prävention mit Fischöl gerät ins Schwimmen
RB (2013) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-013-0856-6
Nutrition support in acute cardiac care
Casaer, M. P., & den Berghe, G. V. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198849346.003.0030
(2020) · Springer Publishing Company eBooks · doi:10.1891/9780826173270.ap08
An Appropriate Energy Intake Proportion of Three Major Nutrients for Treatment of Type 2 Diabetes
Yanai, H., & Katsuyama, H. (2020) · Journal of Endocrinology and Metabolism · doi:10.14740/jem693
Skålhegg, B. S. (2014) · Norsk tidsskrift for ernæring · doi:10.18261/ntfe.12.4.3
Bioactive lipids in cardiovascular disease
Resende, C. X., Amador, A. F., Calvao, J., & Costa, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824043-4.00001-4
Evidence-Based Family Medicine
Pohl, S., & Hastings, K. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_5-1
Role of natural fatty acids in prophylaxis and treatment of cardiovascular diseases
Niezgoda, J., Przerwa, F., Kukowka, A., Aleksandrzak, J., Kotrych, K., & Uzar, I. (2022) · Herba Polonica · doi:10.2478/hepo-2022-0017
Adding Niacin to Statin Therapy in CAD (AIM-HIGH)-2011
McGinley, T. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-25620-2_36
Ganda, O. P., Busch, R. S., Nelson, J. R., & Philip, S. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_25
Metadata
- Authors
- The Risk and Prevention Study Collaborative Group
- Affiliations
- Mario Negri Institute for Pharmacological Research (IT)
- Corresponding author
- The Risk and Prevention Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-05-09
- Volume
- 368
- Issue
- 19
- Pages
- 1800-1808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2614282478
- Cited by
- 510
- References
- 12
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 22 · 2023: 27 · 2022: 31 · 2021: 27 · 2020: 48 · 2019: 33 · 2018: 39 · 2017: 45 · 2016: 45 · 2015: 52 · 2014: 79 · 2013: 38
- FWCI
- 66.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi del Molise (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- omega-3 fatty acids, omega-3 polyunsaturated fatty acids, cardiovascular risk factors, atherosclerosis, cardiovascular mortality, cardiovascular morbidity, myocardial infarction, stroke, olive oil placebo
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Primary Prevention, Risk Factors, Fatty Acids, Omega-3, Proportional Hazards Models, Treatment Failure, Kaplan-Meier Estimate, General Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
